Vaxigrip (Seasonal Influenza Vaccines) Forecast and Market Analysis

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Vaxigrip (Seasonal Influenza Vaccines) Forecast and Market
Analysis
Published on November 2012

Report Summary

Vaxigrip (Seasonal Influenza Vaccines) Forecast and Market Analysis

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, 'Vaxigrip (Seasonal Influenza Vaccines) Forecast and Market
Analysis'. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as
fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently,
trivalent intramuscular vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin
garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as
AstraZeneca's intranasal FluMist and Sanofi's Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such
vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent
formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.

Vaxigrip is a trivalent, inactivated vaccine designed for immunization against seasonal influenza viruses. The vaccine is designed for
administration via intramuscular injection, where the viral antigens elicit an immune response, which helps protect the recipient
against influenza infection. Vaxigrip is marketed by Sanofi as Gripavac in Spain and Inactivated Influenza Vaccine (Split Virion) BP in
the UK. Mutagrip is another trivalent, inactivated influenza vaccine marketed by Sanofi, that is almost identical in formulation and
dosing to Vaxigrip.

Scope

- Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well
as an overview on the competitive landscape.
- Detailed information on Vaxigrip including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Vaxigrip for the top six countries from 2012 to 2022.
- Sales information covered for France, Germany, the UK, Italy, India and China.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for seasonal influenza
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Vaxigrip performance
- Obtain sales forecast for Vaxigrip from 2012 to 2022 in France, Germany, the UK, Italy, India and China.

Table of Content

Vaxigrip (Seasonal Influenza Vaccines) Forecast and Market Analysis (From Slideshare) Page 1/5


1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 5
2 Introduction 6
2.1 Catalyst 6
2.2 Related Reports 6
3 Disease Overview 9
3.1 Etiology and Pathophysiology 9
3.1.1 Etiology 9
3.1.2 Pathophysiology 13
3.2 Symptoms 14
3.3 Prognosis 14
4 Disease Management 15
4.1 Influenza Vaccination Policy 15
5 Competitive Assessment 17
5.1 Overview 17
5.2 Strategic Competitor Assessment 17
5.3 Product Profile - Vaxigrip/Mutagrip 20
5.3.1 Overview 20
5.3.2 Efficacy 21
5.3.3 Safety 22
5.3.4 SWOT Analysis 22
5.3.5 Forecast 24
6 Appendix 25
6.1 Bibliography 25
6.2 Abbreviations 29
6.3 Methodology 29
6.4 Forecasting Methodology 30
6.4.1 Vaccine Coverage 30
6.4.2 Influenza Vaccine Tender System Assumptions 31
6.4.3 General Pricing Assumptions 31
6.4.4 Individual Vaccine Assumptions 32
6.5 Physicians and Specialists Included in this Study 33
6.6 Primary Research - Prescriber Survey 34
6.7 About the Authors 35
6.7.1 Authors 35
6.7.2 Global Head of Healthcare 36
6.8 About GlobalData 37
6.9 Contact Us 37
6.10 Disclaimer 37

List of Tables

1.1 List of Tables
Table 1: Notable Influenza Pandemics 13



Table 2: Symptoms of Influenza 14
Table 3: Influenza Vaccination Recommendation Committees by Country 15
Table 4: Most Administered Influenza Vaccines by Country in the Global Markets, 2012 16
Table 5: Leading Influenza Vaccines, 2012 19
Table 6: Product Profile - Vaxigrip 21
Table 7: Laboratory-Confirmed Influenza Infection Rates in Vaccine or Placebo Recipients and their Household Contacts 22
Table 8: Vaxigrip SWOT Analysis, 2012 23
Table 9: Global Sales Forecasts ($m) for Fluzone ID, 2012-2022 24
Table 10: Epidemiology and Market Forecast Chinese Influenza Vaccination Rates (%), 2012-2022 31
Table 11: Physicians Surveyed, By Country 34

List of Figures

1.2 List of Figures
Figure 1: Influenza Virus Structure 9


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.

Vaxigrip (Seasonal Influenza Vaccines) Forecast and Market Analysis

Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 6 995.00 Quantity: _____

Site License--USD 13 990.00 Quantity: _____

Corporate License--USD 20 985.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Vaxigrip (Seasonal Influenza Vaccines) Forecast and Market Analysis

Recommandé

Recommandé

Contenu connexe

En vedette

En vedette (18)

Plus de ReportLinker.com

Plus de ReportLinker.com (20)

Vaxigrip (Seasonal Influenza Vaccines) Forecast and Market Analysis